Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7070)
All Articles published online
|
Publishing Process of This Article
|
Jun 14, 2015 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li XX, Liang L, Huang LY, Cai SJ. Standard chemotherapy with cetuximab for treatment of colorectal cancer. World J Gastroenterol 2015; 21(22): 7022-7035 [PMID: 26078581 DOI: 10.3748/wjg.v21.i22.7022] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i22/7022.htm |
| Number | Citing Articles |
| 1 |
Bao T. Le, Prithi Raguraman, Tamer R. Kosbar, Susan Fletcher, Steve D. Wilton, Rakesh N. Veedu. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. Molecular Therapy - Nucleic Acids 2019; 14: 142 doi: 10.1016/j.omtn.2018.11.007
|
| 2 |
De-Dong Cao, Hui-Lin Xu, Xi-Ming Xu, Wei Ge. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis. Oncotarget 2017; 8(32): 53631 doi: 10.18632/oncotarget.19022
|
| 3 |
Septiara Putri, Siti Rizny F. Saldi, Levina Chandra Khoe, Ery Setiawan, Amila Megraini, Benjarin Santatiwongchai, Ryan R. Nugraha, Vetty Y. Permanasari, Mardiati Nadjib, Sudigdo Sastroasmoro, Armansyah Armansyah. Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11253-y
|
| 4 |
Svetlana Miroshnichenko, Olga Patutina. Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00488
|
| 5 |
Gil Mullin, Michal Sternschuss, Yosef Landman, Aaron Sulkes, Baruch Brenner. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World Journal of Gastrointestinal Oncology 2023; 15(11): 1913-1924 doi: 10.4251/wjgo.v15.i11.1913
Abstract(352) |
Core Tip(409) |
Full Article(HTML)(1028)
|
Full Article with Cover (PDF)-1134K(55)
|
Full Article (Word)-555K(20)
|
Audio-124K(3)
|
Peer-Review Report-323K(40)
|
Answering Reviewers-89K(43)
|
Full Article (PDF)-842K(68)
|
Full Article (XML)-115K(40)
|
Times Cited (0)
|
Total Visits (3585)
|
Open
|
| 6 |
Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, Christos Vaklavas, Nisha Mohindra, Aparna Kalyan, Maria Matsangou, Ricardo Costa, Benedito Carneiro, Victoria M. Villaflor, Massimo Cristofanilli, Francis J. Giles. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 2017; 8(9): 16052 doi: 10.18632/oncotarget.14109
|